Biohaven plans pivotal trial starts and key data releases in 2026, advancing treatments for epilepsy, obesity, and immune diseases.

Biohaven announced plans to initiate pivotal clinical trials mid-2026 for its novel protein degrader therapies targeting IgA nephropathy and Graves' disease. The company expects topline results in the second half of 2026 from its epilepsy program using a selective Kv7 ion channel activator and from a Phase 2 obesity study with a myostatin-activin pathway inhibitor. Additional progress includes ongoing trials in early Parkinson's disease and advanced endometrial cancer, with no major safety issues reported. Biohaven reported a reduced net loss in Q1 2026 and maintains a strong cash position of approximately $352 million, positioning it well for upcoming milestones and continued development across its neuroscience, immunology, and oncology pipeline.